Therapeutic in Situ Analgesic Implant for improved Oral-Facial Post-Operative Pain Outcomes
Award amount
$390,335Program and phase
SBIR · Phase IAward year
2019Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- EPIGEN BIOSCIENCES INC
- Proposal award date
- 2019-09-19
- Contract end date
- 2020-09-18
- UEI
- L1EDVCGK2327
- Solicitation number
- PA18-574
- Topic code
- NIDCR
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel Methods for Nicotinic Receptor Modulation in the Treatment of Post-Operative Pain
- Novel Product Formulation toModulate Alpha7 Nicotinic Receptors for Therapy in Stroke Recovery
- New Therapy for the Treatment of Primary Biliary Cholangitis.
- Candidate selection of a LPAR1 antagonist for therapeutic application in NASH
- Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- RegendoGEL for guided pulp and dentin regeneration
- CraniaMap: Joint Solution for Auto-Segmentation and Landmarking from CBCT Scans
- Improving Caries Diagnosis with Targeted Nanoparticle-Enhanced AI-Assisted Intraoral Imaging
- Epigenetic Compounds Stimulating Dental Bone Repair
- AI-linked cytomics-on-a-chip to enable near-real time identification and management of oral lichenoid lesions in primary care
Research funding history
25 SBIR/STTR records share this UEI (2012–2025). Reported award amounts total $20,235,589. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services